Large-scale testing (Phase 3)Study completedNCT00536393What this trial is testingTreatment of Disseminated High Grade LymphomaWho this might be right forLymphoma French Innovative Leukemia Organisation 100
Large-scale testing (Phase 3)Ended earlyNCT00841945What this trial is testingTreatment of Aggressive Localized LymphomaWho this might be right forB Cell Lymphoma French Innovative Leukemia Organisation 334
Testing effectiveness (Phase 2)Study completedNCT01562977What this trial is testingStudy to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLWho this might be right forAggressive LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 82
Early research (Phase 1)Study completedNCT04231747What this trial is testingCC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forLymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL) Juno Therapeutics, a Subsidiary of Celgene 24
Testing effectiveness (Phase 2)Study completedNCT01582776What this trial is testingStudy of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell LymphomaWho this might be right forFollicular Lymphoma Patients (Phase IB)Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) The Lymphoma Academic Research Organisation 317
Testing effectiveness (Phase 2)Study completedNCT00842595What this trial is testingEfficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasWho this might be right forDiffuse Large B-Cell Lymphoma French Innovative Leukemia Organisation 50